Pfizer (PFE) Q3 2026 Earnings Review: Newer medicines support a higher profit outlook
Earnings results
- EPS beat 18.4%
Actual: $0.87 adjusted · Cons.: $0.7350
- Revenue beat 4.6%
Actual: $16.583B · Cons.: $15.85B
- Guidance raised
2026 sales $62–64B vs $60.5–62.5B; adjusted EPS $2.95–3.05 vs $2.80–3.00.
What the company reported
Pfizer raised its 2026 sales and profit outlook as growth in newer medicines helped offset shrinking COVID-related revenue. Non-COVID revenue growth and higher guidance show how the newer portfolio is replacing declining COVID sales.
Q3 2026 earnings recap
Pfizer raised its 2026 sales and profit outlook as growth in newer medicines helped offset shrinking COVID-related revenue.
- Adjusted profit per share of $0.87 beat the $0.74 consensus, while revenue of $16.58 billion topped the $15.85 billion forecast.
- The new outlook calls for $62–64 billion in sales and adjusted profit of $2.95–3.05 per share, up from $60.5–62.5 billion and $2.8–3.00.
- Revenue excluding COVID products grew 7% after removing currency effects, with Eliquis and Padcev among the main drivers.
- Reported profit per share fell 9% to $0.56, and the outlook includes a roughly $0.1-per-share Innovent licensing charge.
- At the November 2 close of $30.67, shares traded at about 10.2 times the midpoint of the new adjusted profit outlook.
- Shares were about 0.4% below the prior close before open on November 3, with $30.1–30.45 support and $30.9–31.05 resistance worth watching.
The next test is whether newer drugs and pipeline progress can sustain growth as COVID demand falls and patent and pricing pressures persist.
Financials, technicals and earnings
Charts through Nov 2, 2026.
Technical setup and risks
The November 2 close held above recent support, but the first completed session after results will test that recovery; drug pricing and patent losses remain risks.
AI-assisted earnings research with verified issuer results. Charts use the stated completed session. Educational information; investing involves risk.